Entos Pharmaceuticals and L-CMD Research Foundation Join Forces to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy
Entos Pharmaceuticals Inc has announced a strategic collaboration with the L-CMD Research Foundation aimed at accelerating the development of transformative therapies for LMNA-related congenital muscular dystrophy (L-CMD), a devastating and currently untreatable genetic disorder. The partnership represents a significant step forward in the application of next-generation genetic medicine platforms to address urgent unmet medical needs in rare and ultra-rare diseases.
L-CMD is an exceptionally rare and severe form of congenital muscular dystrophy caused by mutations in the LMNA gene. The condition affects an estimated 200 children worldwide and is characterized by progressive muscle degeneration, life-threatening cardiac complications such as arrhythmias, and a distinctive clinical symptom often described as “dropped head syndrome.” The disease typically presents early in life and progresses rapidly, leaving patients and their families with limited clinical options and a poor prognosis. At present, there are no approved therapies capable of halting or reversing disease progression, making the need for innovative treatment approaches both urgent and critical.
The collaboration between Entos and the L-CMD Research Foundation seeks to address this gap by combining advanced delivery technology with cutting-edge gene editing strategies. At the center of this effort is Entos’ proprietary Fusogenix proteolipid vehicle (PLV) platform, a non-viral delivery system designed to enable safe, efficient, and repeatable administration of genetic cargo. Unlike traditional viral vectors, which can trigger immune responses and limit the possibility of redosing, Fusogenix PLV technology offers a potentially safer and more flexible approach to delivering therapeutic genes or gene-editing components directly into target cells.
This platform advantage is particularly important in diseases like L-CMD, where sustained or repeated therapeutic intervention may be necessary to achieve long-term clinical benefit. By enabling redosable delivery, the Fusogenix system opens the door to treatment paradigms that were previously difficult or impossible to implement using conventional gene therapy methods.
The partnership will also leverage insights and innovations from Entos’ ongoing Duchenne muscular dystrophy (DMD) program. Specifically, the company has been developing muscle-targeted PLV formulations designed to enhance delivery efficiency to skeletal and cardiac muscle tissues—key areas affected in both DMD and L-CMD. By adapting and refining these formulations for L-CMD, the collaboration aims to accelerate the development timeline and improve the likelihood of therapeutic success.
In addition to delivery technology, the collaboration will incorporate novel gene editing approaches aimed at correcting or mitigating the underlying genetic mutations responsible for L-CMD. These approaches may include advanced genome editing tools capable of repairing defective DNA sequences or modulating gene expression in a precise and controlled manner. When combined with the Fusogenix platform, these technologies have the potential to create a truly disease-modifying—or even curative—therapy.
Entos brings to the collaboration not only its proprietary technology but also extensive expertise in genetic medicine development, manufacturing, and regulatory strategy. As a clinical-stage company, it has established critical infrastructure to support the translation of early-stage research into clinical applications. This includes a Good Manufacturing Practices (GMP) facility located in Carlsbad, California, which is equipped to produce high-quality drug substances for preclinical and clinical studies.
Looking ahead, Entos is also planning the development of a new research and development center along with an additional GMP manufacturing facility in Edmonton, Alberta. These investments are expected to further strengthen the company’s capacity to advance multiple genetic medicine programs simultaneously, including those targeting rare diseases like L-CMD. By maintaining in-house manufacturing capabilities, Entos aims to streamline production processes, ensure quality control, and reduce the time required to bring therapies from the laboratory to the clinic.
This integrated approach is particularly valuable in the context of rare diseases, where traditional drug development pathways can be slow, costly, and often unviable due to small patient populations. By combining innovative technology with efficient manufacturing and regulatory strategies, Entos is positioning itself to overcome many of the barriers that have historically limited progress in this space.
John Lewis, Chief Executive Officer of Entos Pharmaceuticals, emphasized the company’s commitment to addressing unmet needs in rare diseases through innovation and collaboration. He highlighted the limitations of conventional drug development approaches, noting that despite significant advances in gene editing and molecular biology, many children with rare conditions like L-CMD continue to lack effective treatment options. According to Lewis, partnerships like the one with the L-CMD Research Foundation are essential for bridging this gap and ensuring that promising technologies reach the patients who need them most.
He also pointed to emerging regulatory pathways, particularly those being explored by agencies such as the U.S. Food and Drug Administration (FDA), which are designed to facilitate the development and approval of therapies for rare and life-threatening conditions. These pathways may include accelerated approval mechanisms, adaptive trial designs, and increased flexibility in clinical requirements, all of which can help bring innovative treatments to patients more quickly.
Hannah Lowe, President of the L-CMD Research Foundation, echoed this sense of urgency and optimism. She expressed enthusiasm about partnering with Entos and underscored the importance of combining scientific innovation with patient-focused advocacy. The foundation plays a critical role in funding research, raising awareness, and connecting stakeholders across the scientific and medical communities to drive progress in L-CMD.
Lowe noted that the collaboration represents more than just a research initiative—it is a concerted effort to build a viable treatment pathway for a disease that has long been overlooked. By aligning the foundation’s deep understanding of patient needs with Entos’ technological and operational capabilities, the partnership aims to accelerate the transition from research to real-world therapeutic solutions.
Importantly, the collaboration also reflects a broader shift in the rare disease landscape, where patient organizations are increasingly taking an active role in driving research and development. By working directly with biotech companies, these organizations can help prioritize research efforts, facilitate patient recruitment for clinical studies, and ensure that therapeutic development remains aligned with the needs of the community.
As the program moves forward, the combined team will focus on advancing preclinical research, optimizing delivery systems, and preparing for investigational new drug (IND)-enabling studies. These steps are critical for demonstrating the safety and efficacy of the proposed therapies and for securing regulatory approval to initiate clinical trials.
While significant challenges remain, including the technical complexities of gene editing and the need for robust clinical validation, the collaboration between Entos Pharmaceuticals and the L-CMD Research Foundation represents a promising step toward a future where effective treatments—and potentially cures—are available for even the rarest and most devastating genetic diseases.
For families affected by L-CMD, this initiative offers a renewed sense of hope. By harnessing the power of advanced genetic medicine and fostering strong collaborative partnerships, the effort aims to transform the outlook for patients and redefine what is possible in the treatment of rare neuromuscular disorders.
About L-CMD and the Research Foundation
L-CMD Research Foundation is a nonprofit formed in 2020 to urgently translate scientific research into treatments for LMNA-related congenital muscular dystrophy (L-CMD). The Houston-based nonprofit was created by the Corman family, Mark Corman and Hannah Lowe, after their younger son, Austin, was diagnosed with L-CMD when he was five months old.
L-CMD is a severe form of muscular dystrophy characterized by progressive muscle weakness, heart arrhythmia and “dropped head;” it is thought to affect at least 200 children worldwide. Knowing that Austin’s condition would progressively worsen, leading to death, and that there are currently no treatments nor cures, the family launched a nonprofit to raise awareness and funds to work on L-CMD. For more information, visit www.lcmdresearch.org.
About Entos Pharmaceuticals Inc
A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. Since its inception in 2016, Entos® has been dedicated to advancing next-generation genetic medicines using our proprietary Fusogenix™ PLV™ drug delivery system. The Fusogenix PLV platform is formulated with FAST proteins to enable the delivery of nucleic acid to target cells through direct fusion.
Entos is pioneering the development of life-changing medicines for patients and has partnered with global companies, such as Eli Lilly, to accelerate and expand the impact of our platform. Entos Pharmaceuticals Inc. is headquartered in Edmonton, Canada, with its wholly owned U.S. and U.K. subsidiaries based in San Diego, California, and London, United Kingdom, respectively. For more information, visit www.entospharma.com, or follow Entos on LinkedIn. Entos® word mark and design logo, FusogenixTM and PLVTM are registered trademarks of Entos Pharmaceuticals Inc. All other trademarks and registered trademarks are the property of their respective owners.
Source Link:https://www.businesswire.com/
